trial

A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.

NCTId NCT00500201
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 18 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2007-07-25
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
18 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
—
Start
2007-05-24
Primary completion
2007-07-25
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
SB- 773812 60 mgSB- 773812 120 mg

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

1 total
London, United Kingdom

Facts & assertions

4 sourced
Enrollment
18
Phase
PHASE1
Primary Completion Date
2007-07-25
Status
COMPLETED
relationships
The graph out of here
drug
SB- 773812 60 mg
drug
SB- 773812 120 mg
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication